Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
News Mar 21, 2007
Arrowhead Research Corporation has announced that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multiple, systemic dosing with Calando's lead siRNA therapeutic candidate.
Calando is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to create targeted siRNA therapeutics. Its lead anti-cancer therapeutic candidate contains a linear cyclodextrin polymer, the siRNA, and a targeting agent. The formulation self assembles into nanoparticles that protect the siRNA from nuclease degradation in serum.
The Company says that one important result of the study was the lack of a significant immune response to the siRNA, demonstrating that the formulation is well tolerated at doses much higher than those previously shown to have anti-cancer effects.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019